Chris Boerner, Bristol Myers Squibb CEO (Tierney L. Cross/Bloomberg via Getty Images)
Bristol Myers touts long-term efficacy of recently acquired Karuna drug
Fresh off closing its $14 billion acquisition of Karuna Therapeutics a few weeks ago, Bristol Myers Squibb is presenting long-term data for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
